Firm
Publication of the UPC’s annual report and adoption of the procedural rules of the Patent Mediation and Arbitration Centre were also among major developments
Tarun Khurana, founding partner of Khurana & Khurana, discusses juggling tasks, why every hour has a value, and the importance of ‘trusting the process’
The variety of winners demonstrates that the UPC is now a core benchmark rather than an experimental consideration, while junior lawyers are becoming more deeply involved in key work
Sheppard, which has hired 14 IP partners in the last 12 months, has cited client demand for expert counsel in SEP, ITC, and district court disputes
Sponsored
Sponsored
-
Sponsored by ZaccoManaging IP sat down with Patrik Lindahl of Zacco and Alessandra Vercelloni of OpSec to learn about the often-overlooked threat to brands posed by the grey market and parallel imports -
Sponsored by CASPrior art searches play a critical role in shaping effective scientific intellectual property strategies. This article, originally published by CAS, highlights the importance of thorough analysis to safeguard R&D investments and ensure patentability
-
Sponsored by CASJoin Managing IP and CAS at 3pm GMT (4pm CET) on December 4 to hear scientific intellectual property search experts explain how a tailored freedom-to-operate analysis can help avoid infringement and facilitate the path to market
-
Sponsored by Tahota Law FirmCharles Feng of Tahota Law Firm begins a two-part guide to intellectual property protection in China by considering the general provisions, before focusing on the key issues and legal framework concerning trademarks
-
Sponsored by Tahota Law FirmCharles Feng of Tahota Law Firm concludes a two-part series on intellectual property protection in China by looking at copyright, unfair competition, and a change to the appeals procedure for technology-related disputes
-
Sponsored by MaiwaldChristian Meyer and Gisela Grabow of Maiwald discuss potential changes to the EU pharmaceutical regulation and their potential impact on data and market protection timelines for medicinal products
